

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin act⦠read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
$68.15
Price+0.89%
$0.60
$8.108b
Mid
-
Premium
Premium
-14317.0%
EBITDA Margin-15815.0%
Net Profit Margin-6036.1%
Free Cash Flow Margin$87.211m
+372.1%
1y CAGR+141.8%
3y CAGR+114.9%
5y CAGR-$751.944m
-27.5%
1y CAGR-25.0%
3y CAGR-38.9%
5y CAGR-$6.30
-19.8%
1y CAGR-14.0%
3y CAGR-24.2%
5y CAGR-$521.123m
$1.437b
Assets$1.958b
Liabilities$1.197b
Debt83.3%
-1.8x
Debt to EBITDA-$453.381m
-13.4%
1y CAGR-14.4%
3y CAGR-26.4%
5y CAGR